Litigation Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Docket		Date Filed	2016-05-27
Court	District Court, D. Delaware	Date Terminated	2019-01-10
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To
Patents	9,259,421
Link to Docket	External link to docket

Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-05-27				External link to document
2016-05-27	30		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,259,421 B2. (Attachments: #…2016 10 January 2019 1:16-cv-00397 830 Patent Defendant District Court, D. Delaware	External link to document
2016-05-27	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number: 9,259,421 B2. (klc) (Entered: …2016 10 January 2019 1:16-cv-00397 830 Patent Defendant District Court, D. Delaware	External link to document

Orexo AB v. Actavis Elizabeth LLC, 1:16-cv-00397: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Orexo AB prevailed against Actavis Elizabeth LLC in Hatch-Waxman litigation over Zubsolv, Orexo’s buprenorphine/naloxone sublingual tablet for opioid dependence. The dispute centered on U.S. Patent No. 8,940,330. The District of Delaware found the asserted claims valid and infringed, and the Federal Circuit affirmed the key obviousness ruling in 2018. Actavis’s ANDA therefore faced a patent-based launch barrier until the relevant patent protection expired or was otherwise resolved. [1, 2]

What drug and patent were at issue in Orexo v. Actavis?

The case involved Zubsolv, a sublingual tablet containing buprenorphine hydrochloride and naloxone hydrochloride. Orexo markets Zubsolv for maintenance treatment of opioid dependence as part of a complete treatment program that includes counseling and psychosocial support. The product competes primarily with Indivior’s Suboxone products.

The principal patent was U.S. Patent No. 8,940,330, titled "Pharmaceutical composition for treatment of opioid dependence." The patent covered aspects of a rapidly dissolving sublingual composition containing buprenorphine and naloxone. Orexo asserted the patent against Actavis’s abbreviated new drug application for a generic version of Zubsolv. [1, 3]

Key case data

Item	Information
Case	Orexo AB v. Actavis Elizabeth LLC
District court	U.S. District Court for the District of Delaware
Civil action	1:16-cv-00397
Statutory framework	Hatch-Waxman Act, including 21 U.S.C. § 355(j) and 35 U.S.C. § 271(e)(2)
Plaintiff	Orexo AB
Defendant	Actavis Elizabeth LLC, an Allergan/Actavis generic-drug affiliate
Product	Zubsolv, buprenorphine/naloxone sublingual tablets
ANDA	Actavis ANDA for a generic buprenorphine/naloxone sublingual product
Principal patent	U.S. Patent No. 8,940,330
Federal Circuit decision	903 F.3d 1265 (Fed. Cir. 2018)
Core issues	Infringement, obviousness, claim construction, objective indicia of nonobviousness

What was the litigation timeline?

The action was filed after Actavis submitted an ANDA and provided Orexo with a Paragraph IV certification challenging the asserted patent. Orexo sued within the statutory 45-day period, triggering the Hatch-Waxman litigation stay that generally prevents FDA approval of the ANDA for up to 30 months, subject to earlier court resolution or other statutory events. [1, 4]

Orexo v. Actavis timeline

Date	Event
2015	U.S. Patent No. 8,940,330 issued to Orexo-related patent interests
2016	Actavis submitted an ANDA with a Paragraph IV challenge; Orexo filed the Delaware action
2017	The District of Delaware ruled for Orexo on the principal validity and infringement issues
2017-2018	Actavis appealed to the U.S. Court of Appeals for the Federal Circuit
Sept. 2018	Federal Circuit issued its decision in Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265
After appellate decision	The asserted patent remained an obstacle to an immediate Actavis generic launch

The case was an ANDA infringement action rather than a conventional damages case involving commercial sales of an accused product. The principal remedy was prospective exclusion of the generic product from the market during the patent term, rather than a large past-damages award.

What did the District of Delaware decide?

The District of Delaware rejected Actavis’s invalidity challenge to the asserted claims of the ’330 patent and found infringement based on the proposed ANDA product. The central validity issue was obviousness under 35 U.S.C. § 103.

Actavis argued that the claimed buprenorphine/naloxone sublingual formulation would have been obvious based on prior-art opioid-dependence treatments, known sublingual delivery techniques, and routine formulation optimization. Orexo argued that the claimed product had a specific combination of formulation properties and performance characteristics that the prior art did not make obvious.

The district court credited Orexo’s evidence concerning:

• The technical differences between the claimed formulation and the prior art.
• The formulation’s sublingual performance.
• Evidence of commercial success for Zubsolv.
• Industry praise and other objective indicia supporting nonobviousness.
• The absence of a sufficiently persuasive reason for a skilled formulator to combine the prior-art teachings in the claimed manner.

The court also rejected Actavis’s infringement position, concluding that the ANDA product fell within the asserted claims. Under Hatch-Waxman law, the proposed ANDA product is evaluated as described in the ANDA and related product materials. [1]

What did the Federal Circuit decide?

The Federal Circuit affirmed the district court’s determination that the asserted claims were not invalid for obviousness. The appellate decision focused on whether the district court properly evaluated the prior art and the objective indicia of nonobviousness.

In Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265, the Federal Circuit held that the district court did not clearly err in finding the claims nonobvious. The appellate court accepted the district court’s evaluation of the prior-art combination and its treatment of objective evidence, including commercial success and other secondary considerations. [2]

The Federal Circuit’s decision is important for formulation patent litigation because it rejected an argument that the claimed pharmaceutical composition was merely the result of routine optimization. The court treated the formulation’s performance and the evidence surrounding Zubsolv’s market acceptance as relevant to the obviousness analysis.

Federal Circuit holding

Issue	Result
Obviousness	Asserted claims upheld as nonobvious
Prior-art combination	Actavis did not establish that the claimed combination was adequately motivated
Objective indicia	District court’s consideration of commercial success and related evidence upheld
Infringement	Orexo’s infringement position remained intact
Practical consequence	Actavis could not obtain an immediate generic launch based on the challenged ANDA

The appellate ruling did not establish that every Zubsolv-related patent was valid or enforceable. Its holding was tied to the claims and record presented in the appeal involving the ’330 patent.

What were Actavis’s Paragraph IV arguments?

Actavis’s Paragraph IV challenge asserted that the relevant patent claims were invalid and/or would not be infringed by the proposed generic product. The principal defense was obviousness.

The technical dispute involved whether the claimed buprenorphine/naloxone formulation could be reached through ordinary formulation work using known ingredients, known ratios, and known sublingual delivery approaches. Actavis relied on prior art concerning opioid-dependence treatment and sublingual dosage forms.

Orexo responded that the prior art did not provide an adequate reason to select the claimed combination or predict its relevant properties. Orexo also relied on objective evidence that the commercial product achieved results that supported patentability.

The case illustrates a recurring risk in ANDA litigation: a generic company may have a credible invalidity theory based on known ingredients, yet still lose if the branded company establishes that the specific claimed combination produced unexpected or commercially meaningful results and that the prior art did not supply a sufficient motivation to combine.

How strong was Orexo’s patent position?

The ’330 patent was strong in the litigation record because Orexo secured favorable findings at both the district court and Federal Circuit levels. The strongest aspects of the estate were:

1. The patent was directed to a commercially important dosage form rather than only a broad therapeutic indication.
2. The infringement case was based on the ANDA product design, allowing Orexo to litigate before generic commercialization.
3. Orexo established a persuasive nonobviousness record involving formulation performance and objective indicia.
4. The Federal Circuit affirmed the core validity ruling.

The patent’s litigation strength should not be confused with estate-wide protection. A single appellate victory does not resolve the validity, scope, or enforceability of continuation patents, later-issued formulation claims, manufacturing patents, or method-of-use patents.

Patent-strength assessment

Factor	Assessment
Claim subject matter	Commercial formulation and sublingual delivery technology
Infringement posture	Favorable; based on the ANDA product
Validity record	Favorable at trial and on appeal
Obviousness risk	Reduced after the Federal Circuit ruling
Design-around risk	Remained relevant because formulation claims can often be avoided through changes in excipients, dosage form, or manufacturing process
Enforcement value	High during the remaining patent term because the case involved a marketed product

What was the Orange Book and FDA status?

The case was linked to the FDA approval pathway for generic Zubsolv through Actavis’s ANDA. A Paragraph IV certification is a regulatory assertion that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The certification permits the patent holder to file a patent infringement action before generic approval.

FDA approval and commercial launch are separate from patent validity. FDA may approve an ANDA after regulatory review, but an approval can remain subject to patent-related restrictions, court orders, settlement terms, or a statutory stay.

Zubsolv was approved by the FDA in 2013 as a buprenorphine/naloxone sublingual tablet. The product is not a biologic, so biosimilar provisions under the Biologics Price Competition and Innovation Act do not apply. Any competitive entry is governed by the small-molecule ANDA framework, including Paragraph IV litigation and potential 180-day generic exclusivity. [3, 4]

When did the relevant patent protection expire?

The precise commercial entry date depends on the patent listed in the Orange Book, any patent-term adjustment or extension, pediatric exclusivity, court orders, and any later settlement or license. The ’330 patent was the operative patent in the reported Orexo v. Actavis appeal, but Zubsolv’s broader patent estate may include continuation patents and additional listed patents with different expiration dates.

A patent-expiration analysis should therefore distinguish:

• The expiration date of the ’330 patent.
• Any patent-term adjustment.
• Any pediatric exclusivity period.
• Later-issued continuation or formulation patents.
• Method-of-use patents and their FDA use codes.
• Any agreement governing an authorized or licensed generic launch.

The public appellate decision establishes the validity outcome for the ’330 patent but is not, by itself, a complete Orange Book chronology for every Zubsolv patent. [2, 3]

Did Orexo and Actavis settle the litigation?

The reported Federal Circuit decision reflects a merits-based appellate resolution of the central dispute. The appellate record does not establish a settlement as the basis for the judgment.

A settlement could have commercial terms that are not fully described in a judicial opinion, including:

• An agreed generic entry date.
• A license to launch before patent expiration.
• An authorized-generic arrangement.
• Supply or manufacturing rights.
• Restrictions on a specific ANDA product.
• Covenants relating to later patents.

The reported decision should therefore be read as a merits ruling on the ’330 patent, not as proof that all commercial issues between the parties were permanently resolved.

Which companies challenged Zubsolv patents?

Actavis was the defendant in the case identified by civil action number 1:16-cv-00397. Other generic-drug manufacturers may have pursued separate ANDAs or separate patent litigation involving Zubsolv, but those proceedings should not be conflated with this action.

The competitive field included:

• Orexo, the Zubsolv developer and marketer.
• Actavis, the ANDA applicant and litigation defendant.
• Indivior, the developer and marketer of Suboxone.
• Generic manufacturers pursuing buprenorphine/naloxone products through ANDAs.

The principal competitive issue was whether an ANDA applicant could enter with a product sufficiently close to Zubsolv to compete on therapeutic and commercial grounds while avoiding valid formulation claims.

What generic launch risks remained after the case?

Actavis faced several possible launch scenarios:

Scenario	Business consequence
Launch after patent expiration	Lawful entry, subject to FDA approval and other listed patents
Launch under a license	Entry controlled by settlement or license terms
At-risk launch before final patent resolution	Exposure to damages, injunction, and possible market disruption
Design-around product	Potentially avoids the asserted claims but may require new formulation, bioequivalence, and regulatory work
Entry after invalidity of later patents	Timing depends on the rest of the patent estate

The Federal Circuit ruling materially reduced the probability that Actavis could defeat the ’330 patent through the asserted obviousness theory. It did not eliminate risks arising from other patents or from a noninfringement position based on a modified product.

Did the case involve biosimilar risk?

No. Zubsolv is a small-molecule drug product, not a biologic. The relevant competitive pathway was an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Biosimilar concepts such as reference-product exclusivity, the Purple Book, and the BPCIA patent-exchange process were not applicable.

What licensing and manufacturing barriers mattered?

The principal technical barrier was the formulation itself. A generic applicant needed to establish pharmaceutical equivalence and bioequivalence while managing claim scope relating to:

• Sublingual dosage-form architecture.
• Buprenorphine and naloxone composition.
• Excipients and their functional effects.
• Dissolution and disintegration behavior.
• Manufacturing controls.
• Taste, stability, and dosage uniformity.

Formulation patents can be commercially significant even when the active ingredients are old. A generic company may be able to use the same active ingredients but still face infringement risk if its dosage form reproduces the patented formulation characteristics.

Manufacturing know-how can create a separate barrier, but the reported case principally concerned patent infringement and obviousness rather than a standalone trade-secret dispute. No publicly reported licensing arrangement should be treated as established solely from the appellate opinion.

What is the commercial significance of the ruling?

The ruling protected Orexo’s position in the Zubsolv market against the specific Actavis ANDA challenge. The commercial value depended on Zubsolv sales, the duration of remaining patent protection, the presence of Suboxone and other buprenorphine/naloxone products, and the timing of additional generic approvals.

The case also created precedent favorable to branded companies defending formulation patents. It confirms that a formulation claim may survive an obviousness challenge when the record shows:

• The prior art did not provide a sufficient reason to select the claimed formulation.
• The claimed properties were not predictable.
• The product achieved meaningful commercial success.
• Objective evidence is tied to the claimed features rather than to unclaimed brand or marketing attributes.

Key Takeaways

• Orexo sued Actavis after an ANDA Paragraph IV challenge involving a generic Zubsolv product.
• The principal patent was U.S. Patent No. 8,940,330.
• The District of Delaware upheld the asserted claims and found infringement.
• The Federal Circuit affirmed the core nonobviousness ruling in 2018.
• The case reduced Actavis’s ability to launch by defeating its principal validity theory.
• Zubsolv is a small-molecule product subject to ANDA rules, not biosimilar rules.
• The decision did not resolve every patent in the broader Zubsolv estate.
• Generic launch timing remained dependent on patent expiration, later-issued patents, FDA approval, and any separate agreement.
• The ruling strengthened Orexo’s litigation position for formulation-based patent protection.

FAQs About Orexo AB v. Actavis Elizabeth LLC

What was the main patent in Orexo v. Actavis?

The principal patent was U.S. Patent No. 8,940,330, covering aspects of Orexo’s buprenorphine/naloxone sublingual formulation used in Zubsolv.

Did Actavis invalidate Orexo’s Zubsolv patent?

No. Actavis did not prevail on its principal obviousness challenge. The Federal Circuit affirmed the key ruling that the asserted claims were not invalid for obviousness.

Was the case a Paragraph IV litigation?

Yes. Actavis’s ANDA included a Paragraph IV patent certification, and Orexo filed an infringement action under the Hatch-Waxman framework.

Is Zubsolv protected by biosimilar exclusivity?

No. Zubsolv is a small-molecule drug. Its generic competition is governed by the ANDA pathway rather than the biosimilar pathway.

Does the Federal Circuit decision cover all Zubsolv patents?

No. The decision addressed the patent claims and issues presented in the appeal, principally involving the ’330 patent. Other Zubsolv-related patents require separate analysis.

References

1. Orexo AB v. Actavis Elizabeth LLC, No. 1:16-cv-00397, U.S. District Court for the District of Delaware.

2. Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265 (Fed. Cir. 2018).

3. U.S. Food and Drug Administration. (2013). Zubsolv approval materials and prescribing information.

4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j); Patent Act, 35 U.S.C. § 271(e)(2).